Non-alcoholic fatty liver disease (NAFLD) is a spectrum of liver disorders. It is defined by the
presence of steatosis in more than 5% of hepatocytes with little or no alcohol consumption …

Cytochromes P450 (CYP) are a major source of variability in drug pharmacokinetics and
response. Of 57 putatively functional human CYPs only about a dozen enzymes, belonging …

An initiation-promotion protocol was used to test the hypothesis that unleaded gasoline (UG)
vapor acts as a liver tumor promoter in female mice under exposure conditions in which UG …

CYP3A is an enzyme subfamily in the cytochrome P450 (CYP) superfamily and includes
isoforms CYP3A4, CYP3A5, CYP3A7, and CYP3A43. CYP3A enzymes are indiscriminate …

Gender differences in schizophrenia have been reported in different aspect of the course of
disease and may urge special clinical interventions for female patients. Current literature …

Sex differences in pharmacokinetics and pharmacodynamics characterize many drugs and
contribute to individual differences in drug efficacy and toxicity. Sex-based differences in …

ATP-binding cassette transporter B1 (ABCB1; P-glycoprotein; multidrug resistance protein 1)
is an adenosine triphosphate (ATP)-dependent efflux transporter located in the plasma …

The liver is necessary for survival. Its strategic localisation, blood flow and prominent role in
the metabolism of xenobiotics render this organ particularly susceptible to injury by …

Women more commonly present with acute liver failure, autoimmune hepatitis, benign liver
lesions, primary biliary cirrhosis, and toxin-mediated hepatotoxicity. Women less commonly …

Abstract Cytochrome P450 3A4 (CYP3A4) metabolizes∼ 50% of all clinically used drugs.
Although CYP3A4 expression varies widely between individuals, the contribution of genetic …